$ZVRA Reports Q4 2025 Revenue Growth Amidst Pipeline Advancements
Zevra Therapeutics, Inc. (ZVRA) reported its financial results for the fourth quarter and full year ended December 31, 2025, highlighting significant revenue growth and continued progress in its rare disease pipeline. The company posted **net product revenue of $15.2 million** for Q4 2025, primarily driven by robust sales of its attention-deficit/hyperactivity disorder (ADHD) treatment, **AZSTARYS®**. […]
$ZVRA Reports Q4 2025 Revenue Growth Amidst Pipeline Advancements Read More »

